Now FDA Approved

A New Oral Therapy in Women’s Health

Read the press release

Our journey of impact

Come with us as we remember where we’ve been, and look forward to where we’re going.

Learn more

Latest news

If you are a member of the news media and have questions or need additional information, please contact our communications team.

May 29, 2020

FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women

May 27, 2020

AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio

May 21, 2020

AbbVie Announces 26 Nonprofits Selected for the COVID-19 Community Resilience Fund

May 15, 2020

AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio
Read More

You must be logged in to view this item.

This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?